Blue Trust Inc. Increases Stock Holdings in Solventum Co. (NYSE:SOLV)

Blue Trust Inc. boosted its position in shares of Solventum Co. (NYSE:SOLV) by 2.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,872 shares of the company’s stock after acquiring an additional 161 shares during the period. Blue Trust Inc.’s holdings in Solventum were worth $549,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Geneos Wealth Management Inc. purchased a new position in shares of Solventum during the 4th quarter valued at $58,000. Exchange Traded Concepts LLC grew its position in Solventum by 1,593.6% during the fourth quarter. Exchange Traded Concepts LLC now owns 14,650 shares of the company’s stock worth $968,000 after buying an additional 13,785 shares in the last quarter. IVC Wealth Advisors LLC increased its stake in Solventum by 8.9% in the 4th quarter. IVC Wealth Advisors LLC now owns 7,243 shares of the company’s stock worth $478,000 after acquiring an additional 594 shares during the last quarter. Global Trust Asset Management LLC raised its holdings in shares of Solventum by 137.5% in the 4th quarter. Global Trust Asset Management LLC now owns 570 shares of the company’s stock valued at $38,000 after acquiring an additional 330 shares in the last quarter. Finally, Nisa Investment Advisors LLC raised its holdings in shares of Solventum by 2.2% in the 4th quarter. Nisa Investment Advisors LLC now owns 33,546 shares of the company’s stock valued at $2,216,000 after acquiring an additional 708 shares in the last quarter.

Analyst Ratings Changes

Several research analysts recently weighed in on the stock. Morgan Stanley upped their price objective on shares of Solventum from $60.00 to $73.00 and gave the stock an “equal weight” rating in a research report on Monday, November 11th. Piper Sandler increased their price target on shares of Solventum from $71.00 to $75.00 and gave the stock a “neutral” rating in a report on Friday, November 8th. Stifel Nicolaus initiated coverage on shares of Solventum in a report on Tuesday, October 8th. They set a “buy” rating and a $82.00 price objective for the company. Finally, Mizuho initiated coverage on Solventum in a research note on Wednesday, December 4th. They issued a “neutral” rating and a $70.00 target price on the stock. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating and one has given a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $68.29.

Solventum Stock Performance

Shares of NYSE:SOLV opened at $75.21 on Friday. The company has a current ratio of 1.15, a quick ratio of 0.83 and a debt-to-equity ratio of 2.45. The company’s fifty day moving average is $70.00 and its 200 day moving average is $66.98. Solventum Co. has a 52 week low of $47.16 and a 52 week high of $96.05.

Solventum (NYSE:SOLV) last released its earnings results on Thursday, November 7th. The company reported $1.15 earnings per share for the quarter, missing analysts’ consensus estimates of $1.38 by ($0.23). The firm had revenue of $2.08 billion during the quarter, compared to the consensus estimate of $2.05 billion. As a group, equities research analysts predict that Solventum Co. will post 6.58 EPS for the current fiscal year.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.